Phase 4
N=84
Hip Scope Fascia-iliaca (FI) Block Study
Hip Dysplasia · Femoroacetabular Impingement · Acetabular Labrum Tear
Bottom Line
View on ClinicalTrials.gov: NCT02365961 ↗Enrolled (actual)
84
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Visual Analog Scale — 2.65; 2.50 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- ropivicaine (Drug); clonidine (Drug); Epinephrine (Drug); Noropin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- The Hawkins Foundation
- Primary completion
- Jun 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analog Scale |
2.65; 2.50 | — |
| SECONDARY Opioid Consumption |
26.87; 30.32 | — |
Summary
Patients undergoing a hip scope procedure will be recruited for this study. They will be randomized to either receive a nerve block or no nerve block (pain medicine only). Pain levels and clinical outcomes will be assessed through 3 months post-operatively.
Eligibility Criteria
Inclusion Criteria
- Scheduled for outpatient hip arthroscopy
- American Society of Anesthesiologists (ASA) 1-3
Exclusion Criteria
- Prior surgery on ipsilateral hip
- ASA 4-6
- Chronic narcotic usage over 6 months or more than the equivalent of 20mg of morphine per day
- Current or prior placement of a spinal cord stimulator or intrathecal pump for pain control purposes
- Allergy to amide local anesthetics
- Contraindication to regional anesthesia
- BMI > 40
- Females who are pregnant or plan to get pregnant during the course of the study
Data sourced from ClinicalTrials.gov (NCT02365961). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.